title: Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines.
abstract: The use of cisplatin (CDDP) as a potential radiosensitizer in tumors is controversial. Reports about CDDP interaction with radiation range from high radiosensitization to a clear sub-additive effect. We examined the effect of the combination of different concentrations of CDDP with radiation in murine mammary adenocarcinoma (EMT-6) and human ovarian carcinoma (OV-1063) cell lines. CDDP was given in the dose range of 0.01-3.0 micrograms/ml and radiation in the dose range of 1-6 Gy. A methylene blue assay of cell density was used for the evaluation of cell survival and rate of proliferation in 96-microwell plates. The validity of this assay for evaluation of cell survival was verified by colony-forming assay and radiolabeled thymidine uptake. The dose response to CDDP for both OV-1063 and EMT-6 cells lines was examined; the ID50 was 0.06 and 0.9 micrograms/ml respectively. A sub-additive effect of the combination of radiation with CDDP was clearly observed in the two cell lines tested; the increase in dose of each modality resulted in a decrease of the relative contribution on the effect of the other. These findings question the rationale of combining CDDP with radiation for the enhancement of tumor response, since with the increase in the dose of either modality the additional effect of the other decreases.
authors.affiliation: Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Gorodetsky
authors.forename: X
authors.initials: X
authors.lastname: Mou
authors.forename: M R
authors.initials: MR
authors.lastname: Pfeffer
authors.forename: T
authors.initials: T
authors.lastname: Peretz
authors.forename: F
authors.initials: F
authors.lastname: Levy-Agababa
authors.forename: A M
authors.initials: AM
authors.lastname: Vexler
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy; D000818:Animals; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000532:radiotherapy*; D008751:Methylene Blue; D051379:Mice; D010051:Ovarian Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D013936:Thymidine; D014407:Tumor Cells, Cultured / Q000528:radiation effects; D014410:Tumor Stem Cell Assay
chemical_list: D002945:Cisplatin; D008751:Methylene Blue; D013936:Thymidine